Reaxa has spun out its antibody drug purification technology business. The new company, ADC Biotechnology, will use IP licensed from Reaxa and aims to deliver significant reduction in manufacturing costs for the new generation of cancer drugs based on antibodies.
Manufacturing Chemist
Monday 18 October 2010
Reaxa spins out antibody tech
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment